Kelley Shannon T sold $431K of MDGL

Kelley Shannon T (General Counsel) sold 1,077 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $400.00 ($0.43M total) on 2026-11-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kelley Shannon T
Published Nov 6, 2026, 9:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MDGL
Neutral
medium confidence
Mentioned
$MDGL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDGLNeutralLow
01

Why it matters

The filing provides a fresh, primary source of insider activity, but the transaction size is modest relative to the company's market cap.

02

Market read

A small insider sell by a senior officer; likely limited price impact.

03

What to watch

Potential upcoming clinical data or regulatory events could outweigh the impact of this modest insider sale.

Relevance 3/10Novelty 3/10Timing: after-hours filing on 2026‑11‑06

Background

SEC Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$MDGLNeutralMedium confidence
Context

General Counsel Kelley Shannon T sold 1,077 shares of Madrigal Pharmaceuticals for $430,800 via a 10b5‑1 plan, reducing her holdings to 10,397 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

A $430k sale by a senior officer is a primary disclosure but modest in scale; traders may view it as a minor bearish signal.

Market effects

Minimal impact on the biotech sector; insider sales are routine.

No broader regional effect.

Limited to Madrigal shareholders.

Counterpoint

The sale could be unrelated to company fundamentals and may not affect price.

Key entities

  • Madrigal Pharmaceuticals, Inc.

    Biotech firm developing therapies for rare diseases.

  • Kelley Shannon T

    General Counsel and officer at Madrigal.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

$MDGLMed

Madrigal reports real-world data on liver disease drug Rezdiffra

Madrigal Pharmaceuticals (MDGL) presented real-world data on its liver disease drug Rezdiffra at a liver disease conference. Studies showed 37% to 55% of patients achieved at least 25% improvement in liver stiffness after a year, with 83% to 93% improving or stabilizing. Safety findings were consistent with clinical trials. Rezdiffra is approved for treating adults with MASH.

$MDGLMedAI 8/10

Madrigal (MDGL) Q3 2026 Earnings Call Transcript

Madrigal Pharmaceuticals (MDGL) reported Q3 2026 net sales of $431M, up 50% YoY, driven by demand for Rezdiffra. The company had 55,850 active Rezdiffra patients, nearly double the previous year. Madrigal expects the U.S. F2/F3 MASH market to grow 30% by year-end, with Rezdiffra penetrating about 1% of the total opportunity.